Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
about
Using existing drugs as leads for broad spectrum anthelmintics targeting protein kinasesRevealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arraysEffects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer CellsCDK inhibitors in clinical development for the treatment of cancer.The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicityHistone Deacetylases Positively Regulate Transcription through the Elongation Machinery.Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.Synthesis and tautomerization of hydroxylated isoflavones bearing heterocyclic hemi-aminals.A novel liposomal formulation of flavopiridol.Cyclosporin A enhances colchicine-induced apoptosis in rat cerebellar granule neurons.JNK-independent activation of c-Jun during neuronal apoptosis induced by multiple DNA-damaging agents.Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity.Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia.Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor.Combined treatment with D-allose, docetaxel and radiation inhibits the tumor growth in an in vivo model of head and neck cancer.CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents.The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.Molecular targets for cell cycle inhibition and cancer therapy
P2860
Q27336465-195ECFF1-948E-484D-8FD5-EBB521E245CEQ34412619-F10AF2F4-DC90-4549-8DC4-92DD5F20C59CQ34487091-709654FE-0185-48BF-9290-78F55D2E94CCQ35143997-1FF5EC6A-1AB5-40F2-A171-31C51F0DDA0AQ35931388-486EAFFC-C0E7-46FA-8A2A-282CE0F3AF75Q36247797-911D3FD6-53C5-47B4-858F-923780CAD835Q37070115-711BF67D-6EF3-488E-AE46-BB33172CDDCDQ38873112-E827DDE7-BB6B-4939-8470-CAF3CFF31648Q41522043-CAC27F34-03EC-49E4-BEAA-8FA6DC0CDC89Q41900653-45F914DC-357F-495F-9DD4-008F6B07264FQ42266658-3CBF2029-0EC9-4EC8-8914-369DFE8EE33FQ44396309-6AA2D9F9-820C-4D3A-82DB-83EE2008AD27Q44429631-D1A82D21-0E39-40B6-A11F-A880A76C68B0Q44605542-E8F539BE-851A-4BD1-B477-8CA6BE8D0CCBQ46188282-D614C9CA-6B7A-4971-B2BC-6297DD6B835BQ49874995-CCFDD9D9-6F4A-4932-B85F-56106184720CQ53060280-5C45EE31-1579-4D0B-999E-1E8D6CCAACC0Q54977960-4A3A9E64-C6AE-4D42-A29E-DC63CF3D0C29Q58884834-E04FE5A3-38F2-4ADE-AD36-A719F03AFC5D
P2860
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@ast
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@en
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@nl
type
label
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@ast
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@en
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@nl
prefLabel
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@ast
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@en
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@nl
P2093
P2860
P356
P1476
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
@en
P2093
Adrian M Senderowicz
Edward A Sausville
Suoping Zhai
William D Figg
P2860
P304
P356
10.1345/APH.1A162
P407
P577
2002-05-01T00:00:00Z